All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, August 19, 2022
Home » Blogs » BioWorld MedTech Perspectives » SCOTUS passes on Stengel: What’s next?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

SCOTUS passes on Stengel: What’s next?

June 25, 2014
By Mark McCarty
No Comments

The preemption waiting game goes on at 1 First St. NE, Washington
The preemption waiting game goes on at 1 First St. NE, Washington

The news is out that the Supreme Court (SCOTUS) passed on the chance to hear Medtronic v. Stengel, one of the more recent cases tackling FDA’s preemption of state tort law for PMA devices, so maybe it’s time for a preemption check-up.

First, it may be instructive to ask “why not Stengel?” The case had bounced from a district court (which dismissed the suit against Medtronic) to the U.S. Ninth Appeals Court, which handed it back to the lower court after seeming to suggest the plaintiff’s attorneys have little chance of success. One might assume Medtronic would let it go at that, but the company nonetheless applied for cert, which the Supreme Court took the better part of a year to consider.

Medtronic may have figured it had little to lose by taking the case to Washington, but the company might also have imagined the odds were long that the Court would grant cert in the first place. Either way, next up is Medtronic v. Caplinger. The company’s Infuse bone morphogenic is alleged to have been the subject of off-label discussions between the company and doctors (specifically about anterior versus posterior access to the spine), which is a somewhat different set of issues than those brought forth by Stengel, which was a failure-to-warn claim for an infusion pump presumably used on label.

Also on tap for Medtronic (why is it always Medtronic?) is Coleman v. Medtronic, which according to this analysis was decided for the plaintiff in a rather qualified fashion. Not much has happened since the California Court of Appeals (a state court) decided the case in January, but one assumes it would end up in Ninth Appeals should it graduate to the federal level.

The interesting thing about Caplinger is that it presents the third federal appeals court venue (Tenth Appeals Court) for preemption of the past four years or so and hence might trigger another examination of preemption at SCOTUS (bear in mind that the last time the Supreme Court examined this issue was Riegel in 2008, another Medtronic case, and another case in which Allison Zieve of Public Citizen represented the plaintiff).

A quick tally of the two concluded appeals court cases leaves us with one case that probably had no chance of changing anything (Stengel), and one that was probably a long shot to change things had the Supreme Court heard it, namely the Sprint Fidelis electrophysiology lead litigation decided in the Eighth Appeals Court four years ago affirming preemption.

The losing party in Caplinger will appeal for cert, there’s no question about that. If SCOTUS passes again, it will likely hear from the loser in Coleman should that case get through the federal appeals system. Given the foregoing, it seems unlikely the Supreme Court will take Caplinger if Tenth Appeals affirms preemption. None of this argues, however, that SCOTUS wouldn't pass on Caplinger if the case takes a very limited swipe at preemption.

On the other hand, the Supreme Court may feel it's time to act if Coleman hits the appeals court system and generates a decision that seems to add yet more noise to the preemption question.

Absent any change to the overall make-up of the Supreme Court, we might assume any preemption cases the Court takes would come out reinforcing at least the principal tenets of preemption. Still, there is a tremendous amount of activity and groups like Public Citizen seem determined to put an end to preemption.

About the only thing the layperson can say conclusively about all this is that any decision at SCOTUS on this question in the near future won’t change things much. A death or retirement of one of the conservative jurists while President Obama is still in office would torque the situation drastically, but that might be the only window for ending preemption over the next decade, given the voters’ collective penchant for switching parties in the White House every eight years.

All the same, one would be well advised not to fall asleep on this issue.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 19, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 19, 2022.
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
  • TPOXX

    Siga leads monkeypox antiviral research, amid lack of interest from big pharma

    BioWorld
    After declarations from the World Health Organization and the U.S. government that monkeypox is a public health emergency, attention is turning to the pharma...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing